{"schema_version":"secwatch.filing_event.v1","accession":"0000059478-26-000008","form_type":"8-K","ticker":"LLY","cik":"0000059478","company_name":"ELI LILLY & Co","filed_at":"2026-02-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.454066+00:00","generated_at":"2026-05-16T05:07:53.265801+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Lilly Q4 revenue up 43% to $19.3B; EPS $7.39 (+51%); FY2026 guidance $80-83B","bullets":["Q4 revenue $19.3B (+43% YoY); reported EPS $7.39 (+51%); non-GAAP EPS $7.54 (+42%), both incl. $0.52 acquired IPR&D.","FY2026 guidance: revenue $80-83B; non-GAAP EPS $33.50-$35.00.","FDA approved Kwikpen for tirzepatide; filed orforglipron for obesity in US, Japan, and EU.","Positive Phase 3 results for Taltz+Zepbound combo in psoriatic arthritis and retatrutide for knee osteoarthritis.","Agreement with U.S. government to expand access to obesity medicines for millions of Americans."],"urls":{"canonical":"https://secwatch.observer/filing/0000059478-26-000008","json":"https://secwatch.observer/filing/0000059478-26-000008.json","markdown":"https://secwatch.observer/filing/0000059478-26-000008.md","text":"https://secwatch.observer/filing/0000059478-26-000008.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/59478/000005947826000008/0000059478-26-000008-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/59478/000005947826000008/lly-20260204.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T05:07:53.265801+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}